Moreover, intermediate-dose XZR had a similar beneficial effect, as it reversed the high levels of TNF-α (15.91 ± 6.93 pg/mg protein), IL-1β (38.20 ± 0.76 pg/ml), and IL-6 (17.76 ± 3.02 pg/ml) in rats with migraine (p < 0.05). Here, IL6 is linked to migraine disorder.